Merck

Keytruda wins FDA nod for treating Kidney Cancer Merck’s Keytruda has recently got the U.S. FDA approval to be administered for Kidney Cancer. The drug Keytruda was approved in combination with Pfizer’s Inlyta for the treatment of advanced renal carcinoma. This therapy could prove to be serious for competition B...

AgomAb Therapeutics raises USD 23.5 million for its agomAbs A Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23.5 million in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Adv...

Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has...

Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum.  But for more than two decades now Scientists from everywhere have been working on the “amyloid hypothesis". It has been a long-standing theory that brains of the people affected ...

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...

Could a virus be a treatment therapy? Confusing, isn't it? On the face value, it seems no; but on delving deeper, the confusion dissipates. There have been tireless efforts among a section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer ...

Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of ...

Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the develo...

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...